Schizophrenia Research
Volume 98, Issue 1 , Pages 55-65 , January 2008

A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: The QUERISOLA trial

  • Emilio Sacchetti

      Affiliations

    • Department of Psychiatry, Brescia University School of Medicine, Brescia, Italy
    • University Psychiatric Unit, Brescia University School of Medicine and Brescia Spedali Civili, Brescia, Italy
    • Department of Mental Health, Brescia Spedali Civili, Brescia, Italy
    • Centre of Behavioural and Neurodegenerative Disorders, Brescia University and EULO, Brescia, Italy
    • Corresponding Author InformationCorresponding author. University Psychiatric Unit, Brescia Spedali Civili, Piazza Spedali Civili, 1, 25123 Brescia, Italy. Tel.: +39 030 3995233/381749; fax: +39 030 3384089.
    • ,
  • Paolo Valsecchi

      Affiliations

    • University Psychiatric Unit, Brescia University School of Medicine and Brescia Spedali Civili, Brescia, Italy
    • Department of Mental Health, Brescia Spedali Civili, Brescia, Italy
    • ,
  • Giovanni Parrinello

      Affiliations

    • Department of Biomedical Sciences and Biotechnologies, Section of Medical Statistics and Biometry, Brescia University School of Medicine, Brescia, Italy
    • ,
  • for the QUERISOLA Group

Received 6 June 2007 ,Revised 10 September 2007 ,Accepted 12 September 2007.

References 

  1. Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J. Clin. Psychiatry. 2004;65:1624–1633
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders . Fourth Edition. Washington, DC: American Psychiatric Association; 2000;Text Revision
  3. Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst. Rev. 2000;CD001945
  4. Barnes TR. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 1989;154:672–676
  5. Brecher M, Leong R, Stening G, Osterling-Koskinen L, Jones AM. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J. Clin. Psychiatry. 2007;68:597–603
  6. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am. J. Psychiatry. 2005;162:1879–1887
  7. Citrome L, Jaffe A, Levine J, Lindenmayer J-P. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J. Clin. Psychiatry. 2005;66:1512–1516
  8. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 2001;158:765–774
  9. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry. 2003;60:553–564
  10. Duggan L, Fenton M, Rathbone J, Dardennes R, El Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst. Rev. 2005;CD001359
  11. El Sayeh H, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst. Rev. 2006;CD004578
  12. Emsley R, Oosthuizen P. Evidence-based pharmacotherapy of schizophrenia. Int. J. Neuropsychopharmacol. 2004;219–238
  13. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172:1703–1711
  14. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev. 2000;CD002306
  15. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs. 2006;20:293–301
  16. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am. J. Psychiatry. 2006;163:185–194
  17. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev. 2003;CD000440
  18. Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst. Rev. 2005;CD005237
  19. Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Medication selection, dosing, and dose equivalence. J. Clin. Psychiatry. 2003;64(Suppl 12):21–51
  20. Kasper S, Rosillon D, Duchesne I. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int. Clin. Psychopharmacol. 2001;16:179–187
  21. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  22. Kraus JE, Sheitman BB, Cook A, Reviere R, Lieberman JA. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. J. Clin. Psychiatry. 2005;66:1564–1568
  23. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581–1589
  24. Lieberman J, McEvoy JP, Perkins D, Hamer RH. Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone. In: Poster P.3.163 presented at the 18th Congress of the European College of Neuropsychopharmacology, Amsterdam, The Netherlands, 22–26 October. 2005;
  25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353:1209–1223
  26. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. A new five factor model of schizophrenia. Psychiatr. Q. 1994;65:299–322
  27. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93
  28. Psychopharmacology Research Branch . N. Abnormal Involuntary Movement Scale (AIMS). In:  Guy W editors. National Institute of Mental Health. 1976;p. 534–537
  29. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry. 2002;47:27–38
  30. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand., Suppl. 1970;212:11–19
  31. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst. Rev. 2004;CD000967
  32. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr. Res. 2005;79:145–155
  33. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2003;28(Suppl 1):9–26
  34. Tandon R, Jibson MD. Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Int. J. Psychiatry Clin. Pract. 2005;9:204–212
  35. Welleck S. Testing Statistical Hypotheses of Equivalence. Boca Raton: Chapman and Hall/CRC; 2003;
  36. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J. Clin. Psychiatry. 2006;67:1093–1103

PII: S0920-9964(07)00405-7

doi: 10.1016/j.schres.2007.09.011

Schizophrenia Research
Volume 98, Issue 1 , Pages 55-65 , January 2008

Article Tools

* Image Usage & Resolution